neurodegeneration – Page 2

The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice

mycolabadmin

This study tested whether psilocybin (an active compound from magic mushrooms) combined with eugenol (a natural compound from cloves) could reduce brain inflammation in mice. Researchers gave mice a substance that triggers inflammation in the brain and then treated them with these compounds before or after the inflammation started. The combination treatment, especially at a 1:50 ratio of psilocybin to eugenol, significantly reduced multiple inflammatory markers in the brain, suggesting this combination could potentially be helpful for treating brain inflammation-related conditions.

Sporoderm-removed ganoderma lucidum spore powder (S-GLSP) alleviates neuroinflammation injury by regulating microglial polarization through inhibition of NLRP3 inflammasome activation

mycolabadmin

Researchers found that sporoderm-removed Ganoderma lucidum spore powder (S-GLSP) protects against Alzheimer’s disease by reducing brain inflammation. The supplement works by shifting immune cells in the brain called microglia from a harmful pro-inflammatory state to a protective anti-inflammatory state. This is accomplished by blocking the NLRP3 inflammasome, a key trigger of brain inflammation. In animal and cell studies, S-GLSP improved memory, reduced neuronal damage, and decreased harmful tau protein accumulation.

Assessment of Lab4P Probiotic Effects on Cognition in 3xTg-AD Alzheimer’s Disease Model Mice and the SH-SY5Y Neuronal Cell Line

mycolabadmin

Researchers tested a probiotic supplement called Lab4P on mice genetically engineered to develop Alzheimer’s-like symptoms and on human brain cells exposed to damaging proteins. The supplement successfully improved memory and cognitive function in the mice while protecting brain cells from damage, with stronger benefits when the mice were also on a high-fat diet. These findings suggest that probiotics might help prevent or slow cognitive decline related to Alzheimer’s disease.

Butyrate ameliorates quinolinic acid–induced cognitive decline in obesity models

mycolabadmin

This research shows that overweight and obese individuals have higher levels of a toxic compound called quinolinic acid in their bodies, which is linked to memory problems and brain shrinkage. The good news is that butyrate, a substance naturally produced by gut bacteria when we eat fiber, can protect against these harmful effects. Butyrate works by activating genes that produce brain-derived neurotrophic factor (BDNF), a protein essential for brain health and memory formation. The study suggests that increasing butyrate through diet or supplements could help prevent cognitive decline associated with obesity.

Strain-specific effects of Desulfovibrio on neurodegeneration and oxidative stress in a Caenorhabditis elegans PD model

mycolabadmin

This research shows that different strains of bacteria called Desulfovibrio have very different effects on brain health. When scientists exposed worms to six different strains, they found that environmental strains actually protected against Parkinson’s-like symptoms, while strains from human patients and animals caused more damage. The worms strongly preferred to eat the environmental strains, suggesting they could sense which bacteria were harmful. This highlights how the type of bacteria in our gut matters just as much as the total amount.

N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer’s disease

mycolabadmin

This research reveals how an abnormal RNA molecule called circRIMS2 contributes to Alzheimer’s disease by damaging brain synapses and impairing memory. Scientists found that circRIMS2 levels are elevated through a chemical modification called m6A methylation, and this causes a cascade of events leading to the destruction of important proteins needed for brain communication. The study shows that blocking this damaging pathway using a specially designed peptide can restore memory and synaptic function in Alzheimer’s disease models, offering hope for new therapeutic approaches.

Ganoderic Acid A targeting leucine-rich repeat kinase 2 involved in Parkinson’s disease–A computational study

mycolabadmin

Researchers used computer modeling to test five compounds from Reishi mushrooms against a protein called LRRK2 that is linked to Parkinson’s disease. Ganoderic Acid A showed the strongest binding to this target protein and could potentially be developed into a treatment. The findings suggest that Reishi mushroom compounds may help protect brain cells from the degeneration seen in Parkinson’s disease and warrant further laboratory and animal testing.

Long term worsening of amyloid pathology, cerebral function, and cognition after a single inoculation of beta-amyloid seeds with Osaka mutation

mycolabadmin

Researchers found that a single exposure to mutated amyloid-beta proteins (Aβ Osaka) in the brains of genetically modified mice caused lasting damage over four months. The mutated proteins triggered more severe memory loss, brain connectivity problems, and synapse damage compared to normal amyloid-beta. This suggests that even one encounter with mutated amyloid proteins can set off a chain reaction of disease progression that persists long after initial exposure.

Neuronal TIMP2 regulates hippocampus-dependent plasticity and extracellular matrix complexity

mycolabadmin

Scientists discovered that a protein called TIMP2, which is naturally higher in young blood, plays a crucial role in maintaining brain memory and learning ability. Using laboratory mice, they found that TIMP2 helps keep the brain’s cellular environment flexible by controlling the buildup of structural proteins around nerve connections. Without adequate TIMP2, the brain develops more rigid connections that interfere with forming new memories and creating new brain cells, mimicking changes seen in aging and cognitive decline.

The Biological Activity of Ganoderma lucidum on Neurodegenerative Diseases: The Interplay between Different Active Compounds and the Pathological Hallmarks

mycolabadmin

Reishi mushroom, used in traditional Asian medicine for centuries, contains over 400 bioactive compounds that show promise in protecting the brain from degenerative diseases like Alzheimer’s and Parkinson’s. The mushroom’s components work through multiple pathways to reduce inflammation, fight oxidative stress, and protect neurons from damage. While laboratory and animal studies show encouraging results, human clinical trials are needed to confirm its effectiveness as a treatment.

Disease: neurodegeneration